Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 814 across all filing types
Latest filing 2024-03-03 Regulatory Filings
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DIASORIN RECEIVES FDA 510(K) CLEARANCE FOR ITS LIAISON PLEX® SYSTEM TOGETHER WITH THE LIAISON PLEX® RESPIRATORY PANEL
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Diasorin, identified by the 'Informazione Regolamentata' header and specific filing number (0957-6-2024). The subject is the receipt of FDA 510(K) clearance for a new diagnostic platform (LIAISON PLEX®) and its first panel. This type of announcement, detailing a significant regulatory/product milestone that impacts the company's operations and market position, is typically classified as a general regulatory announcement or a specific update related to operations/products. Since it is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a specific capital event (CAP, SHA), it fits best under the general Regulatory Filings (RNS) category, which serves as a fallback for significant, non-standard announcements, or potentially a Legal/Regulatory update, though the FDA clearance itself is a positive regulatory event rather than a legal proceeding (LTR). Given the context of a formal, time-stamped regulatory disclosure ('Informazione Regolamentata'), RNS is the most appropriate general classification for this type of market-moving news that isn't explicitly covered by other codes.
2024-03-03 English
DIASORIN RICEVE L’AUTORIZZAZIONE FDA 510(K) PER IL LIAISON PLEX® E PER IL PANNELLO RESPIRATORIO “LIAISON PLEX® RESPIRATORY FLEX ASSAY”
Regulatory Filings Classification · 97% confidence The document is a formal announcement from Diasorin, dated March 3, 2024, regarding receiving FDA 510(k) authorization for a new molecular diagnostic platform (LIAISON PLEX®) and a specific respiratory assay. The structure, including the 'Oggetto' (Subject) and the content detailing a significant business/regulatory event (FDA approval), strongly suggests a regulatory or corporate news release. Since it is not a full Annual Report (10-K), a quarterly report (IR), an earnings release (ER), or a transcript (CT), and it is a specific announcement of a regulatory milestone, it fits best under the general 'Regulatory Filings' category (RNS) as a significant, non-standard filing, or potentially a Capital/Financing Update (CAP) if the FDA approval directly leads to a major market expansion/fundraising event, but RNS is the most appropriate general regulatory announcement fallback. Given the context of FDA authorization for a new product line, it is a key regulatory event announcement. It is not an announcement *about* a report (RPA), but the announcement *of* the event itself. Therefore, RNS is the most suitable classification.
2024-03-03 Italian
DiaSorin S.p.A. - 2024 Annual Calendar of Corporate Events
Report Publication Announcement Classification · 99% confidence The document is titled "DiaSorin S.p.A. - 2024 Annual Calendar of Corporate Events". It lists key dates for future corporate actions, including Board of Directors meetings for financial results approval (Q1, Half-Yearly, Q3) and the date for the Annual General Meeting (AGM) to approve 2023 financial statements and remuneration policy. Since the document's primary purpose is to announce the schedule of future corporate events, including the AGM, it is not the AGM material itself, nor is it a full financial report (10-K or IR). It is an announcement detailing future corporate activities. Given the options, this type of forward-looking schedule announcement, especially one detailing the AGM date, is best classified as a general regulatory announcement or a precursor to specific events. However, since it explicitly mentions the date for the 'Annual General Meeting' approval, it relates closely to AGM information. Since it is a calendar of events rather than the meeting materials or voting results, and it is a formal regulatory filing (Informazione Regolamentata), the most appropriate classification among the specific options is either RNS (Regulatory Filings - fallback) or potentially related to AGM/DIV if it were more specific. Because it is a formal announcement of future dates for key corporate events, including the AGM and financial report releases, and it is short and structured like a regulatory notice, RNS (Regulatory Filings) is the safest general classification, although it contains elements related to AGM and ER/IR. Given the structure and the explicit mention of the AGM date, it functions as a general corporate update filing.
2024-01-18 English
DiaSorin S.p.A. - Calendario Annuale Eventi Societari 2024
Regulatory Filings Classification · 98% confidence The document is titled 'DIASORIN S.P.A. – CALENARDIO ANNUALE EVENTI SOCIETARI 2024' (Annual Calendar of Corporate Events 2024). It lists scheduled dates for Board of Directors meetings (approving financial results like Q1, Half-Year, Q3, and Full Year 2023 results) and the Annual Shareholders' Meeting (Assemblea degli Azionisti) for approving the 2023 Financial Statements and remuneration policy. This content directly relates to the scheduling and announcement of key corporate governance and financial reporting events, including the AGM. Since it is an announcement detailing the schedule of future corporate events, including the AGM, it fits best under the 'AGM Information' category (AGM-R) as it pertains to the schedule surrounding the Annual General Meeting, or potentially a general Regulatory Filing (RNS) if AGM-R is strictly for meeting materials. Given the explicit mention of the 'Assemblea degli Azionisti' and the schedule for approving the annual accounts, AGM-R is the most specific fit, as it covers AGM-related information, even if it's the schedule rather than the presentation itself. It is not the full 10-K, ER, or IR. It is an announcement of future events, making RPA or RNS possible, but AGM-R is more descriptive of the core subject matter (AGM schedule). I will classify it as AGM-R due to the central role of the shareholder meeting schedule.
2024-01-18 Italian
Communication on total amount of voting rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS pursuant to Article 85-bis, paragraph 4-bis, of Consob Regulation no. 11971/1999'. It explicitly details changes in the total amount of voting rights due to the assignment of increased voting rights to a shareholder. This type of announcement, which reports on the structure of voting rights and shareholder entitlements, aligns most closely with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it is a formal communication regarding voting rights structure, even if it's not the final result of a specific vote, but rather an update to the underlying voting power mechanism. It is not an AGM-R (no meeting materials), 10-K (not annual report), ER (not earnings), or IR (not a comprehensive interim report). The core subject is the calculation and announcement of total voting rights, which fits DVA.
2024-01-08 English
Comunicazione ammontare complessivo dei diritti di voto
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official communication from DiaSorin S.p.A. dated January 8, 2024, titled 'COMUNICAZIONE DELL'AMMONTARE COMPLESSIVO DEI DIRITTI DI VOTO' (Communication of the total amount of voting rights) pursuant to Italian regulation (Regolamento Consob n. 11971/1999). It details a change in the total number of voting rights due to a shareholder gaining enhanced voting rights (voto maggiorato) on 122 ordinary shares. This specific disclosure relates to changes in shareholder voting power and capital structure related to voting rights, which aligns closely with notifications regarding significant share ownership changes or capital structure updates. While it is a regulatory filing, the specific content—reporting the total voting rights and the breakdown of shares with and without enhanced voting rights—is a specialized disclosure. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the closest fit as it deals with changes in ownership structure impacting voting power, although 'SHA' (Share Issue/Capital Change) or 'RNS' (Regulatory Filings) are also possibilities. Given the focus on the total voting rights calculation and the specific mention of enhanced voting rights acquisition, this is a mandatory regulatory disclosure concerning capital/voting structure. Since there isn't a specific code for 'Voting Rights Update,' and it is a formal regulatory announcement, 'RNS' (Regulatory Filings) serves as the most appropriate general category for mandatory, non-standard financial reports, or 'MRQ' if interpreted as a change in significant ownership structure impact. However, the core subject is the total voting rights count, which is often grouped with major shareholding disclosures or general regulatory updates. Given the specific nature of reporting voting rights changes, and lacking a dedicated 'Voting Rights' code, 'MRQ' (Major Shareholding Notification) is a strong candidate as voting rights are intrinsically linked to share ownership thresholds. If interpreted strictly as a general regulatory announcement not fitting other specific categories, RNS applies. I will select MRQ as the subject matter is directly related to the structure of voting rights tied to shareholding, which is the essence of MRQ, even if it's not a simple threshold crossing notification.
2024-01-08 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.